Mitral valve abnormalities were not part of modern pathological and clinical descriptions of hypertrophic cardiomyopathy in the 1950s, which focused on left ventricular (LV) hypertrophy and myocyte fiber disarray. Although systolic anterior motion (SAM) of the mitral valve was discovered as the cause of LV outflow tract obstruction in the M-mode echocardiography era, in the 1990s structural abnormalities of the mitral valve became appreciated as contributing to SAM pathophysiology. Hypertrophic cardiomyopathy mitral malformations have been identified at all levels. They occur in the leaflets, usually elongating them, and also in the submitral apparatus, with a wide array of malformations of the papillary muscles and chordae, that can be detected by transthoracic and transesophageal echocardiography and by cardiac magnetic resonance. Because they participate fundamentally in the predisposition to SAM, they have increasingly been repaired surgically. This review critically assesses imaging and measurement of mitral abnormalities and discusses their surgical relief. (J Am Coll Cardiol 2016;67:1846-58)
was noted in 1974 (24) and was followed by related publications (4, 7, 25, 26) . These investigators described how this displacement positions mitral leaflets anteriorly into the flow stream and also reduces their restraint, causing mitral slack, a necessary component of dynamic SAM (25, 27) . Investigators from the National Institutes of Health (later from Minneapolis) described direct insertion of an anomalous anteriorly displaced papillary muscle into the middle of the anterior mitral leaflet without intervening chordae (9) . These displaced anterior papillary muscles can contact the septum with each beat, causing submitral LV obstruction. Papillary muscle or anomalous chordae insertion into the midleaflet can also tent the mitral leaflet anteriorly into the flow stream. Mitral leaflet elongation and its importance was prominently brought to light by these same investigators (2,3), who also described isolated posterior leaflet SAM occurring when this leaflet is particularly elongated (28) . At about the same time, transesophageal echocardiography (TEE) showed elongated leaflets in patients coming to surgery (29) .
The most common cause of MR in obstruction occurs when the posterior leaflet is not long or mobile enough to move anteriorly with the anterior leaflet, resulting in poor coaptation (29) (30) (31) ; MR is reduced or eliminated by abolition of SAM, either surgically or with optimal pharmacological therapy (12, 29, 31) . The important point is that resolution of the SAM is the therapeutic goal; this improves coaptation and the MR. In this review, mitral abnormalities are discussed according to their prominence and relative frequency in patients coming to surgery. TEE is necessary to resolve any ambiguities about the cause of obstruction when pre-operative imaging is suboptimal and always in the operating room immediately before and after cardiopulmonary bypass. The final operative plan should be confirmed after review of TEE immediately before cardiopulmonary bypass. Because CMR has been increasingly used to precisely demonstrate abnormalities of the mitral apparatus in HCM, we will discuss its utility in detail.
ELONGATED ANTERIOR AND POSTERIOR MITRAL LEAFLETS
The large majority of patients with obstructive HCM have elongated anterior and posterior mitral leaflets, as compared with normal subjects. Elongation has been noted pathologically, on echocardiography, and on CMR (2, 3, 5, 6, 12, 29, 32) . In obstructive HCM, the anterior leaflet averages 34 mm versus 24 mm in normal hearts (5, 12, 29) . We have termed this abnormality the "nightcap" When excessive residual leaflet length contributes to obstruction, excision has been utilized as an ancillary or alternative procedure to leaflet plication.
A2 is often an isolated segment of excessive length, with 2 or 3 extremely slack and thinned-out chordae.
Pre-operative analysis of the echocardiogram often reveals this segment to be inconsequential to coaptation and competence, and direct examination in the operative field suggests that these chordae play no role in preventing flail if removed. A segment of 2 to 5 mm can at times be simply and safely excised Obstructing residual leaflet is shown with a white arrow. LV outflow tract orifices, displayed in black, are on either side of the residual leaflet,
shown with red arrows. High drag profile of the residual leaflet can be appreciated. TEE ¼ transesophageal echocardiography.
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A P R I L 1 9 , 2 0 1 6 : 1 8 4 6 -5 8 ( Figure 5 ). As in plication, judgment on the basis of experience must be exercised when determining the safety of residual leaflet excision.
Another method to stiffen the mitral leaflet has been termed anterior mitral leaflet extension. Here, the anterior leaflet is vertically incised and a stiff pericardial patch is inserted to prevent billowing of the leaflet (17) . This underscores the principle that alternate surgical approaches can be used in an individual patient to achieve optimal relief of LV outflow tract obstruction (18) . However, inserting a pericardial patch requires incising the valve, and can be time- .
A P R I L 1 9 , 2 0 1 6 : 1 8 4 6 -5 8 magnitude correlated with anomalies, independent of septal thickness. Bifid papillary muscle, seen on CMR in Figure 6B , can appear on the echocardiographic short-axis view as an anterior extension and displacement ( Figure 6A ).
The extended myectomy, as described by Messmer 
CLINICAL AND ECHOCARDIOGRAPHIC

RESULTS OF THE RESECT-PLICATE-RELEASE OPERATION
From 1997 to 2015, we operated on 252 patients with obstructive HCM for symptoms and gradients resistant to pharmacological therapy (1,15,16 ). The resect-plicate-release (RPR) techniques used were adopted and modified from the reported surgical experience of others (7, 8, 9, 14, 18) . The mean age was 56 AE 14 years; 55% were men. The average New York Heart Association functional class was 2.8 AE 0. 
Continued on the next page
surgical inspection provide the basis for individual case-by-case judgments regarding the need for mitral plication and papillary muscle release. Plication was performed in 66% of patients; papillary release was performed in 86%. MVR was necessary in 6%.
Concomitant procedures were performed in 35%, with coronary artery bypass graft as the most common (16%). 
CENTRAL ILLUSTRATION Continued
The top left image shows normal anatomy of mitral leaflets as they appear on the apical long-axis view. Sherrid et al.
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Operative mortality was 0.4%. The post-procedural complication rate was 15%; the majority of complications were respiratory compromise in older patients with multiple comorbidities. Complete heart block requiring pacemaker insertion occurred in 6%. Early reoperation was required in 2 patients (0.4%): 1 for ventricular septal defect repair and 1 for MVR.
Length of stay was 7 AE 5 days. There was marked improvement in New York Heart Association functional class for 96%. In our 2012 report, survival at 1, 5, and 10 years was 98%, 98%, and 92%, respectively (16).
We recently reported on detailed echocardiography before and after the resect-plicate-release repair in 77 patients. Pre-operative echocardiographic
anterior mitral length provides a basis to recommend performance of plication and defines its extent.
We recommend plication when the anterior leaflet is (12) . An algorithm describing our use of echocardiography, both transthoracic and TEE, to select which of the "resect," "plicate," or "release" procedures to apply in an individual patient is presented in Figure 11 .
SHOULD MITRAL SURGERY ACCOMPANY MYECTOMY?
There is controversy about whether mitral valve abnormalities should be surgically repaired at the time of myectomy (46) . Some centers generally perform mitral repair in addition to extended myectomy (8, 10, (14) (15) (16) (17) , whereas it is the judgment of others to usually just perform myectomy (1, 47) . It may be a natural surgical approach to comprehensively address all discovered contributors to a patient's SAM, and to not leave unrepaired pathology.
However, because a clinical trial has not been per- 
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obstruction. In patients who come to surgery at many centers, the judgment is made to repair contributing mitral abnormalities whenever they are detected, regardless of the magnitude of septal hypertrophy.
Mitral abnormalities play a particularly important role in patients with mild or moderate hypertrophy.
These patients should not be treated by septal reduction alone (ASA in particular); surgical mitral valve repair in association with septal myectomy is the preferred approach. A number of surgical techniques are available to repair the mitral valve in HCM;
given the great diversity of mitral abnormalities, the proper technique should be selected for the individual patient.
